¼Ò¾Æ±Þ¼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ ÀÌ°ÇÈñ ¼Ò¾Æ¾Ï ±Øº¹»ç¾÷ °øµ¿ ½ÉÆ÷Áö¾ö : 2023-11-17 |
|
¼Ò¾Æ±Þ¼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ ÀÌ°ÇÈñ ¼Ò¾Æ¾Ï ±Øº¹»ç¾÷ °øµ¿ ½ÉÆ÷Áö¾ö : 2023-11-17 ±³À°ÁÖÁ¦ : ¼Ò¾Æ±Þ¼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ ÀÌ°ÇÈñ ¼Ò¾Æ¾Ï ±Øº¹»ç¾÷ °øµ¿ ½ÉÆ÷Áö¾ö ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ ´ã´çÀÚ : ±èÇýÁø À̸ÞÀÏ : hematology@kams.or.kr ±³À°Á¾·ù : ¼Ò¾Æû¼Ò³â°ú Âü¼®¿¹»óÀÎ : 60¸í Áö¿ª : ¼¿ïƯº°½Ã ¼¼ºÎ¼ö°·á : 50,000¿ø ºñ°í
±³À°½Ã°£ 11¿ù 17ÀÏ º£¸£»çÀÌÀ¯È¦ 14:00~14:15 Standare risk ALL(acute lymphoblastic leukemia) ÁÖÈñ¿µ(¼º±Õ°üÀÇ´ë) ±³À°½Ã°£ 11¿ù 17ÀÏ º£¸£»çÀÌÀ¯È¦ 14:15~14:30 High risk ALL(acute lymphoblastic leukemia) ÀÌÀç¿í(°¡Å縯ÀÇ´ë) ±³À°½Ã°£ 11¿ù 17ÀÏ º£¸£»çÀÌÀ¯È¦ 14:30~14:45 Very high risk ALL(acute lymphoblastic leukemia) ±èº¸°æ(¼¿ïÀÇ´ë) ±³À°½Ã°£ 11¿ù 17ÀÏ º£¸£»çÀÌÀ¯È¦ 14:45~15:00 Infnat ALL(acute lymphoblastic leukemia) Çѽ¹Î(¿¬¼¼ÀÇ´ë) ±³À°½Ã°£ 11¿ù 17ÀÏ º£¸£»çÀÌÀ¯È¦ 15:00~15:15 Relapsed ALL(acute lymphoblastic leukemia) ±èÇý¸®(¿ï»êÀÇ´ë) ±³À°½Ã°£ 11¿ù 17ÀÏ º£¸£»çÀÌÀ¯È¦ 15:25~15:40 clinical application of NGS MRD in pediatric ALL(acute lymphoblastic leukemia) È«°æÅÃ(¼¿ïÀÇ´ë ) ±³À°½Ã°£ 11¿ù 17ÀÏ º£¸£»çÀÌÀ¯È¦ 15:40~15:55 Comprehensive genomin analysis project for pediatric hematologic malignancies ±è¸í½Å(°¡Å縯ÀÇ´ë) ±³À°½Ã°£ 11¿ù 17ÀÏ º£¸£»çÀÌÀ¯È¦ 15:55~16:10 CAR-T cell therpay for pediatric ALL(acute lymphoblastic leukemia) requiring HSCT(hematopoietic stem cell transplantation) °ÇüÁø(¼¿ïÀÇ´ë) ±³À°½Ã°£ 11¿ù 17ÀÏ º£¸£»çÀÌÀ¯È¦ 16:40~17:20 Treatment of pediatric cancer À¯Ã¶ÁÖ(¿¬¼¼ÀÇ´ë) ±³À°½Ã°£ 11¿ù 17ÀÏ º£¸£»çÀÌÀ¯È¦ 17:20~18:00 Basic conecpt hematopoietic stem cell and leukemia stem cell Á¶ºó(°¡Å縯ÀÇ´ë )
|
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|